
Current Price | $1.51 | Mkt Cap | $262.2M |
---|---|---|---|
Open | $1.42 | P/E Ratio | -5.84 |
Prev. Close | $1.51 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $1.41 - $1.58 | Volume | 2,539,792 |
52-Wk Range | $0.64 - $2.04 | Avg. Daily Vol. | 3,078,726 |
The Company is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases.
Current Price | $1.51 | Mkt Cap | $262.2M |
---|---|---|---|
Open | $1.42 | P/E Ratio | -5.84 |
Prev. Close | $1.51 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $1.41 - $1.58 | Volume | 2,539,792 |
52-Wk Range | $0.64 - $2.04 | Avg. Daily Vol. | 3,078,726 |
The best Bull and Bear pitches based on recency and number of recommendations.
Obviously this puts them in a tough spot with Fostamatinib but they do have a few bullets left to fire in 2013 along with some cash that was raised at the end of 2012. I think the offering priced at 9.50. Not saying I have much of a valuation model… More
I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!
Read the most recent pitches from players about RIGL.
Recs
COVID trials
Recs
indication for their approved drug.
Recs
https://www.fool.com/investing/2017/08/19/3-top-biotech-stocks-under-5.aspx?source=itxsitmot0000001&lidx=1
Find the members with the highest scoring picks in RIGL.
qubit15 (24.80) Score: +511.91
The Score Leader is the player with the highest score across all their picks in RIGL.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
qubit15 | 24.80 | 1/21/2009 |
![]() |
NS | $6.95 | -78.27% | +433.64% | +511.91 | 0 Comment | |
robo2011 | 33.27 | 11/17/2008 |
![]() |
NS | $6.53 | -76.88% | +407.26% | +484.14 | 0 Comment | |
anticitradeshort | 26.97 | 4/20/2009 |
![]() |
NS | $6.43 | -76.52% | +404.50% | +481.02 | 0 Comment | |
cybob2000 | 44.70 | 10/23/2008 |
![]() |
3W | $15.64 | -90.35% | +385.31% | +475.66 | 0 Comment | |
schwah8 | 98.55 | 10/13/2008 |
![]() |
NS | $18.26 | -91.73% | +363.82% | +455.55 | 0 Comment | |
EV38biotech | < 20 | 11/5/2008 |
![]() |
5Y | $8.60 | -82.44% | +345.29% | +427.74 | 0 Comment | |
Mynx828 | 68.40 | 9/17/2009 |
![]() |
5Y | $7.45 | -79.73% | +300.43% | +380.16 | 0 Comment | |
longtermgrowth09 | 51.15 | 12/17/2009 |
![]() |
5Y | $8.97 | -83.17% | +285.75% | +368.91 | 0 Comment | |
darksider389 | 86.12 | 7/7/2008 |
![]() |
3M | $21.97 | -93.13% | +253.96% | +347.09 | 0 Comment | |
flats66 | 64.14 |
|
![]() |
3Y | $22.71 | -93.35% | +244.63% | +337.98 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.